Investigation Report on China Olmesartan Market, 2010-2019

Hypertension is the most dangerous factor that leads to the occurrence and resulting death of heart disease, cerebrovascular disease and kidney disease. According to the stati…
Reference: 1506191
Price: $2,000.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
6/4/2015
Pages
20
Version:
2010
Charts:
20
Language
  • English
  • Chinese
Format
License

Description
Hypertension is the most dangerous factor that leads to the occurrence and resulting death of heart disease, cerebrovascular disease and kidney disease. According to the statistics of WHO, by 2030, nearly 23.6 million around the world will die of cardiovascular disease especially heart disease and apoplexy each year.
With the change of life styles brought about by economic development, the incidence of hypertension keeps growing in China. The number of hypertension patients is estimated to be 266 million with one in five adults suffering from it. Cardia-cerebrovascular disease is the leading cause of death in China and 50% of it relate to hypertension. Therefore, the effective control of hypertension and prevention of cardia-cerebrovascular disease has become an important health concern for health care workers and the public. On the other hand, patients need long-term pharmacotherapy for hypertension is a controllable disease.
In 1991, olmesartan medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd and was patented in many countries. In Apr. 2002, olmesartan medoxomil was approved by FDA to enter the American market in May. It has now become the best-selling drug in the world after it succeeded in the US market.
Compared with other ARBs, olmesartan medoxomil has distinctive pharmacokinetic properties. It develops fast after entering China with annual sales rising from CNY 4448 in 2010 to CNY 99.07 million and CAGR reaching up to 204.15%. Currently, there are three manufacturers of olmesartan in Chinese market: Shanghai Sankyo Pharmaceuticals Co., Ltd, Shanghai Sine Promod Pharmaceutical Co., Ltd and Beijing Winsunny Pharmaceutical Co., Ltd, among which Shanghai Sankyo Pharmaceuticals Co., Ltd has the biggest market share of 94.45% in 2014 with sales value reaching up to CNY 93.57 million in the same year.
With the increase of the incidence of cardiovascular disease and its number of cases, the market size of olmesartan is estimated to keep expanding in the next few years.

Readers can get at least the following information through this report:
-market size of olmesartan in China
-major manufacturers of olmesartan in the Chinese market and their market share
-retail price of olmesartan in China
-market outlook of olmesartan in China

The author suggests the following groups of people purchase this report:
-manufacturers of cardiovascular system drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in Chinese medicine market, please contact CRI for customized survey service
Table of Contents

1 Related Concepts of Olmesartan
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Olmesartan in China
2.1 Patent and Approval Status of Olmesartan in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Olmesartan in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Olmesartan in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Olmesartan in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Olmesartan in Chinese Hospitals in 2014
6.1 Shanghai Sankyo Pharmaceuticals Co., Ltd (Trade Name: Benicar)
6.2 Shanghai Sine Promod Pharmaceutical Co., Ltd
6.3 Beijing Winsunny Pharmaceutical Co., Ltd

7 Major Manufacturers of Olmesartan in Chinese Market, 2010-2014
7.1 Shanghai Sankyo Pharmaceuticals Co., Ltd
7.2 Shanghai Sine Promod Pharmaceutical Co., Ltd
7.3 Beijing Winsunny Pharmaceutical Co., Ltd

8 Market Outlook of Olmesartan in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Selected Charts
Chart Patent Status of Olmesartan in China
Chart Approval Status of Olmesartan in China
Chart Sales Status of Olmesartan in China, 2010-2014
Chart Sales Value of Olmesartan in China, 2010-2014
Chart Sales Value of Olmesartan in Some Regions in China, 2010-2014
Chart Sales Volume of Olmesartan in China, 2010-2014
Chart Market Size of TOP3 Manufacturers of Olmesartan for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Olmesartan Made by Shanghai Sankyo in China, 2010-2014
Chart Sales Value and Market Share of Olmesartan Made by Beijing Winsunny in China, 2010-2014
Chart Sales Value and Market Share of Olmesartan Made by Shanghai Sine Promod in China, 2010-2014
Chart Sales Value and Market Share of Olmesartan Tablets in China, 2010-2014
Chart Price of Olmesartan Made by Shanghai Sankyo Pharmaceuticals Co., Ltd in Some Chinese Cities in 2014
Chart Price of Olmesartan Made by Shanghai Sine Promod Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Olmesartan Made by Beijing Winsunny Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Scroll